Refine
Has Fulltext
- yes (61)
Is part of the Bibliography
- yes (61)
Year of publication
Document Type
- Journal article (61)
Language
- English (61)
Keywords
- Fabry disease (16)
- chronic kidney disease (12)
- enzyme replacement therapy (9)
- hemodialysis (5)
- mortality (4)
- systematic literature review (4)
- type 2 diabetes (4)
- agalsidase alfa (3)
- agalsidase beta (3)
- cardiovascular events (3)
- end-stage renal disease (3)
- epidemiology (3)
- Chronic kidney disease (2)
- Diabetes mellitus (2)
- Enzyme replacement therapy (2)
- Fabry nephropathy (2)
- Kidney function (2)
- LDL cholesterol (2)
- United States (2)
- blood pressure (2)
- cardiomyopathy (2)
- cardiovascular disease (2)
- cardiovascular morbidity (2)
- convection volume (2)
- diabetes (2)
- diabetes mellitus (2)
- dialysis (2)
- dialysis adequacy (2)
- fibrosis (2)
- genome-wide association (2)
- glomerular filtration rate (2)
- glycemic control (2)
- heart failure (2)
- hemodiafiltration (2)
- hypertrophic cardiomyopathy (2)
- inflammation (2)
- kidney (2)
- left ventricular hypertrophy (2)
- proteinuria (2)
- safety (2)
- stage renal-disease (2)
- 2-dimensional speckle tracking (1)
- A-delta fibers (1)
- ACC/AHA classification (1)
- ASE formula (1)
- African-americans (1)
- Agalsidase beta (1)
- Alpha-Galactosidase (1)
- Alpha-galactosidase (1)
- Amino acids (1)
- Anderson-Fabry Disease (1)
- C-reactive protein (1)
- CKD (1)
- CMR (1)
- Calcium Citrate (1)
- Cardiomyopathy (1)
- Cardiovascular diseases (1)
- Catheter Lock Solution (1)
- Catheter-related Bloodstream Infections (CRBSI) (1)
- Chronic Kidney-disease (1)
- Chronic kidney-disease (1)
- Clinical proteomics (1)
- Clinical trial (1)
- Clinical-trials (1)
- Cohort study (1)
- Cumulative incidence function (1)
- D313Y genotype (1)
- Diabetic nephropathies (1)
- Diabetic-nephropathy (1)
- Dipeptidyl-peptidase IV inhibitors (1)
- Discovery (1)
- Diversity (1)
- EUROASPIRE survey (1)
- Epidemiology (1)
- European Society (1)
- Fabry (1)
- Fabry cardiomyopathy (1)
- Fabry genotype (1)
- Fabry patient (1)
- Fabry phenotype (1)
- Fabry-associated pain (1)
- Family Investigation of Nephropathy and Diabetes (1)
- Female patients (1)
- GLA (1)
- Galactosidase-A gene (1)
- General-population (1)
- Globotriaosylceramide (1)
- Glomerular-filtration-rate (1)
- Glycaemic control (1)
- HLA (1)
- Haemodialysis (1)
- Hazards (1)
- Heart failure (1)
- Hemodialysis-patients (1)
- Hemoglobin A1C (1)
- Homoarginine (1)
- ICD-coding of CKD (1)
- Insulin therapy (1)
- KDIGO (1)
- L-arginine (1)
- LV mass (1)
- Lag time (1)
- Linagliptin (1)
- Lyso-Gb3 (1)
- Mass-spectrometry (1)
- Model (1)
- Mortality (1)
- Natural-history data (1)
- Network (1)
- New mexico (1)
- Nrf2 (1)
- Onset hypertrophic cardiomyopathy (1)
- Oral antidiabetic drugs (1)
- Outcome survey (1)
- Pain (1)
- Pain-related evoked potentials (1)
- Postmarketing Experience (1)
- Prevalence (1)
- Probabilities (1)
- Progression (1)
- Quality of life (1)
- Racial differences (1)
- Regression (1)
- Research design (1)
- Risk (1)
- SF-36 (1)
- SGLT2 inhibitor (1)
- Sample-sizes (1)
- Small fiber neuropathy (1)
- Stage renal-disease (1)
- Subdistribution (1)
- Sudden cardiac death (1)
- Taurolidine (1)
- Teichholz formula (1)
- Tests (1)
- Treatment outcome (1)
- VEMP (1)
- Variants (1)
- X-chromosomal inactivation (1)
- Young-patients (1)
- activated-receptor gamma (1)
- add-on (1)
- adult female patients (1)
- adult male patients (1)
- agalsidase-beta (1)
- agnoists (1)
- albumin excretion rate (1)
- albuminuria (1)
- aldosterone (1)
- alkaline phosphatase (1)
- alpha galactosidase (1)
- alpha-galactosidase-A (1)
- alpha/delta agonist GFT505 (1)
- anaemia (1)
- anemia (1)
- antagonist (1)
- anti-drug antibodies (1)
- anticoagulation (1)
- antidiabetic agents (1)
- arial fibrillation (1)
- atherogenic dyslipidaemia (1)
- atherosclerosis risk (1)
- bardoxolone methyl (1)
- biocompatibility (1)
- biomarker (1)
- biopsy (1)
- biopsy findings (1)
- blood-glucose control (1)
- body weight (1)
- calcification (1)
- canagliflozin (1)
- cancer risk factors (1)
- cardiac dysfunction (1)
- cardiac energy metabolism (1)
- cardiac hypertrophy (1)
- cardiac variant (1)
- cardiovascular death (1)
- cardiovascular magnetic resonance (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular mortality (1)
- cardiovascular munster procam (1)
- cardiovascular outcomes (1)
- cardiovascularm disease (1)
- chronic kidney-disease (1)
- clinical manifestations (1)
- clinical trial (1)
- colestilan (1)
- comorbidity (1)
- consensus conference (1)
- converting enzyme-inhibition (1)
- cornea verticillata (1)
- coronary artery disease (1)
- coronary heart disease (1)
- cortisol (1)
- costs (1)
- creatine synthesis (1)
- cryptogenic stroke (1)
- diabetes complications (1)
- diabetes mellitus type 2 (1)
- diabetic kidney disease (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- dietary sodium restriction (1)
- disease (1)
- doule blind (1)
- dysfunction (1)
- echocardiography (1)
- efficacy (1)
- empagliflozin (1)
- end stage renal disease (1)
- end-stage kidney disease (1)
- erythropoietin (1)
- fabry disease (1)
- failure (1)
- female Fabry patients (1)
- ferritin (1)
- fibroblast growth factor-23 (1)
- focal semental glomerulosclerosis (1)
- fractionation membranev (1)
- free light chains (1)
- gene variant (1)
- genetic renal disease (1)
- genetics (1)
- genome-wide association study (1)
- genotype/phenotype correlation (1)
- genotyping (1)
- global outcomes (1)
- glomerular-filtration-rate (1)
- glomerulonephritis (1)
- haemodiafiltration (1)
- hearing loss (1)
- hemoglobin (1)
- heodialysis patients (1)
- high denisty lipoprotein (1)
- hypercholesterolemia (1)
- hyperphosphataemia (1)
- hypersensitivity (1)
- identification (1)
- immunofluorescence (1)
- impact (1)
- incidence (1)
- induced insulin-release (1)
- infections (1)
- inherited metabolic disorders (1)
- inos (1)
- insufficiency (1)
- intensive glucose control (1)
- iron (1)
- ischemia-reperfusion injury (1)
- italian population (1)
- kidney disease (1)
- left ventricular mass (1)
- left ventricular mass index (1)
- left-ventricular hypertrophy (1)
- linkage (1)
- lipoprotein apheresis (1)
- lipoprotein(a) (1)
- lysosomal storage disease (1)
- lysosomal storage disorder (1)
- macrovascular (1)
- medical dialysis (1)
- medium cut-off dialyzer (1)
- melanoma (1)
- men born (1)
- metformin (1)
- mices (1)
- microvascular (1)
- mineral metabolism (1)
- multiple sclerosis (1)
- myocardial infarction (1)
- myocardial fibrosis (1)
- natural history (1)
- natural-history data (1)
- nerve fibers (1)
- neuropathy (1)
- nictric-oxide (1)
- overload (1)
- oxidative stress (1)
- p.Asn215Ser (1)
- p.N215S (1)
- paediatric patients (1)
- parathyroid hormone (1)
- pathophysiology (1)
- patients’ awareness (1)
- phase IV (1)
- phenotype (1)
- phosphate homeostasis (1)
- phospholipid fatty acids (1)
- physicians’ awareness (1)
- pioglitazone (1)
- placebo (1)
- placebo-controlled trial (1)
- podocyte (1)
- prediction model (1)
- prevalence (1)
- protein-bound uremic toxins (1)
- randomized controlled trial (1)
- randomized controlled-trial (1)
- randomized trial (1)
- randomized trials (1)
- rat kidney (1)
- receptor (1)
- recombination hotspot (1)
- renal disease (1)
- renal dysfunction (1)
- renal fibrosis (1)
- renal function (1)
- renal replacement therapy (1)
- renal system (1)
- renoprotection (1)
- replacement therapy (1)
- residual cardiovascular risk (1)
- risk (1)
- risk factors (1)
- septal hypertrophy (1)
- serum creatinine (1)
- sevelamer (1)
- single nucleotide polymorphisms (1)
- skin diseases (1)
- sudden cardiac death (1)
- sulfonylurea (1)
- survival (1)
- term fenofibrate therapy (1)
- therapeutic options (1)
- therapy (1)
- trial design (1)
- triglyceride-rich lipoproteins (1)
- troponin T (1)
- type 2 (1)
- type-1 diabetes mellitus (1)
- type-2 diabetes mellitus (1)
- urinary protein excretion (1)
- vascular disease (1)
- vertigo (1)
- vitamin D (1)
Institute
- Medizinische Klinik und Poliklinik I (61) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 602133 (1)
Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients.
Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers.
Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance.
Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies.
Fabry disease is a rare X-linked hereditary disease caused by mutations in the AGAL gene encoding the lysosomal enzyme alpha-galactosidase A. Enzyme replacement therapy (ERT) is the current cornerstone of Fabry disease management. Involvement of kidney, heart and the central nervous system shortens life span, and fibrosis of these organs is a hallmark of the disease. Fibrosis was initially thought to result from tissue ischemia secondary to endothelial accumulation of glycosphingolipids in the microvasculature. However, despite ready clearance of endothelial deposits, ERT is less effective in patients who have already developed fibrosis. Several potential explanations of this clinical observation may impact on the future management of Fabry disease. Alternative molecular pathways linking glycosphingolipids and fibrosis may be operative; tissue injury may recruit secondary molecular mediators of fibrosis that are unresponsive to ERT, or fibrosis may represent irreversible tissue injury that limits the therapeutic response to ERT. We provide an overview of Fabry disease, with a focus on the assessment of fibrosis, the clinical consequences of fibrosis, and recent advances in understanding the cellular and molecular mechanisms of fibrosis that may suggest novel therapeutic approaches to Fabry disease.
Background: Diabetes mellitus type 2 (DM2) is highly associated with increased risk for chronic kidney disease (CKD), end stage renal disease (ESRD) and cardiovascular morbidity. Epidemiological and genetic studies generate hypotheses for innovative strategies in DM2 management by unravelling novel mechanisms of diabetes complications, which is essential for future intervention trials. We have thus initiated the DIAbetes COhoRtE study (DIACORE).
Methods: DIACORE is a prospective cohort study aiming to recruit 6000 patients of self-reported Caucasian ethnicity with prevalent DM2 for at least 10 years of follow-up. Study visits are performed in University-based recruiting clinics in Germany using standard operating procedures. All prevalent DM2 patients in outpatient clinics surrounding the recruiting centers are invited to participate. At baseline and at each 2-year follow-up examination, patients are subjected to a core phenotyping protocol. This includes a standardized online questionnaire and physical examination to determine incident micro-and macrovascular DM2 complications, malignancy and hospitalization, with a primary focus on renal events. Confirmatory outcome information is requested from patient records. Blood samples are obtained for a centrally analyzed standard laboratory panel and for biobanking of aliquots of serum, plasma, urine, mRNA and DNA for future scientific use. A subset of the cohort is subjected to extended phenotyping, e. g. sleep apnea screening, skin autofluorescence measurement, non-mydriatic retinal photography and non-invasive determination of arterial stiffness.
Discussion: DIACORE will enable the prospective evaluation of factors involved in DM2 complication pathogenesis using high-throughput technologies in biosamples and genetic epidemiological studies.
BACKGROUND:
This study compared the effects of short-term titrated colestilan (a novel non-absorbable, non-calcium, phosphate binder) with placebo, and evaluated the safety and efficacy of colestilan over 1 year compared with sevelamer, in patients with chronic kidney disease (CKD) 5D.
METHODS:
This prospective multicentre study comprised a 4-week phosphate binder washout period, a 16-week short-term, flexible-dose, treatment period (including a 4-week placebo-controlled withdrawal period) and a 40-week extension treatment phase.
RESULTS:
At Week 16 (the end of the 4-week placebo-controlled withdrawal period), serum phosphorus level was 0.43 mmol/L (1.32 mg/dL) lower with colestilan than placebo (P < 0.001; primary end point). Serum LDL-C level was also lower with colestilan than with placebo (P < 0.001). Both colestilan and sevelamer produced significant reductions from baseline in serum phosphorus levels (P < 0.001), maintained for 1 year, and the proportion of patients achieving target levels of ≤1.78 mmol/L (5.5 mg/dL) or ≤1.95 mmol/L (6.0 mg/dL) at study end were similar (65.3 and 73.3%, respectively, for colestilan, and 66.9 and 77.4%, respectively, for sevelamer). Serum calcium level remained stable in the colestilan group but tended to increase slightly in the sevelamer group (end-of-study increase of 0.035 mmol/L over baseline). Both binders produced similar reductions from baseline in LDL-C level (P < 0.001), and responder rates after 1 year, using a target of <1.83 mmol/L (70 mg/dL) or <2.59 mmol/L (100 mg/dL) were similar in both groups (50.7 and 85.3% for colestilan and 54.0 and 80.6% for sevelamer). Colestilan was generally well tolerated.
CONCLUSIONS:
Colestilan is effective and safe for the treatment of hyperphosphataemia in patients with CKD 5D, and affords similar long-term phosphorus and cholesterol reductions/responder rates to sevelamer.
Background
Anemia is common and is associated with impaired clinical outcomes in diabetic chronic kidney disease (CKD). It may be explained by reduced erythropoietin (EPO) synthesis, but recent data suggest that EPO-resistance and diminished iron availability due to inflammation contribute significantly. In this cohort study, we evaluated the impact of hepcidin-25—the key hormone of iron-metabolism—on clinical outcomes in diabetic patients with CKD along with endogenous EPO levels.
Methods
249 diabetic patients with CKD of any stage, excluding end-stage renal disease (ESRD), were enrolled (2003–2005), if they were not on EPO-stimulating agent and iron therapy. Hepcidin-25 levels were measured by radioimmunoassay. The association of hepcidin-25 at baseline with clinical variables was investigated using linear regression models. All-cause mortality and a composite endpoint of CKD progression (ESRD or doubling of serum creatinine) were analyzed by Cox proportional hazards models.
Results
Patients (age 67 yrs, 53% male, GFR 51 ml/min, hemoglobin 131 g/L, EPO 13.5 U/L, hepcidin-25 62.0 ng/ml) were followed for a median time of 4.2 yrs. Forty-nine patients died (19.7%) and forty (16.1%) patients reached the composite endpoint. Elevated hepcidin levels were independently associated with higher ferritin-levels, lower EPO-levels and impaired kidney function (all p<0.05). Hepcidin was related to mortality, along with its interaction with EPO, older age, greater proteinuria and elevated CRP (all p<0.05). Hepcidin was also predictive for progression of CKD, aside from baseline GFR, proteinuria, low albumin- and hemoglobin-levels and a history of CVD (all p<0.05).
Conclusions
We found hepcidin-25 to be associated with EPO and impaired kidney function in diabetic CKD. Elevated hepcidin-25 and EPO-levels were independent predictors of mortality, while hepcidin-25 was also predictive for progression of CKD. Both hepcidin-25 and EPO may represent important prognostic factors of clinical outcome and have the potential to further define “high risk” populations in CKD.
Background. The purpose of this study was to identify determinants of renal disease progression in adults with Fabry disease during treatment with agalsidase beta.
Methods. Renal function was evaluated in 151 men and 62 women from the Fabry Registry who received agalsidase beta at an average dose of 1 mg/kg/2 weeks for at least 2 years. Patients were categorized into quartiles based on slopes of estimated glomerular filtration rate (eGFR) during treatment. Multivariate logistic regression analyses were used to identify factors associated with renal disease progression.
Results. Men within the first quartile had a mean eGFR slope of –0.1 mL/min/1.73m2/year, whereas men with the most rapid renal disease progression (Quartile 4) had a mean eGFR slope of –6.7 mL/min/1.73m2/year. The risk factor most strongly associated with renal disease progression was averaged urinary protein:creatinine ratio (UP/Cr) ≥1 g/g (odds ratio 112, 95% confidence interval (95% CI) 4–3109, P = 0.0054). Longer time from symptom onset to treatment was also associated with renal disease progression (odds ratio 19, 95% CI 2–184, P = 0.0098). Women in Quartile 4 had the highest averaged UP/Cr (mean 1.8 g/g) and the most rapid renal disease progression: (mean slope –4.4 mL/min/1.73m2/year).
Conclusions. Adults with Fabry disease are at risk for progressive loss of eGFR despite enzyme replacement therapy, particularly if proteinuria is ≥1 g/g. Men with little urinary protein excretion and those who began receiving agalsidase beta sooner after the onset of symptoms had stable renal function. These findings suggest that early intervention may lead to optimal renal outcomes.
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R(3)i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R(3)i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R(3)i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptor alpha agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R(3)i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.
Background: Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that any intervention to mitigate this risk must address CV risk factors beyond glycemia alone. The SGLT-2 inhibitor empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to other antihyperglycemic agents in patients with type 2 diabetes. The aim of the ongoing EMPA-REG OUTCOME (TM) trial is to determine the long-term CV safety of empagliflozin, as well as investigating potential benefits on macro-/microvascular outcomes.
Methods: Patients who were drug naive (HbA(1c) >= 7.0% and <= 9.0%), or on background glucose-lowering therapy (HbA(1c) >= 7.0% and <= 10.0%), and were at high risk of CV events, were randomized (1:1:1) and treated with empagliflozin 10 mg, empagliflozin 25 mg, or placebo (double blind, double dummy) superimposed upon the standard of care. The primary outcome is time to first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke. CV events will be prospectively adjudicated by an independent Clinical Events Committee. The trial will continue until >= 691 confirmed primary outcome events have occurred, providing a power of 90% to yield an upper limit of the adjusted 95% CI for a hazard ratio of <1.3 with a one-sided a of 0.025, assuming equal risks between placebo and empagliflozin (both doses pooled). Hierarchical testing for superiority will follow for the primary outcome and key secondary outcomes (time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina pectoris) where non-inferiority is achieved.
Results: Between Sept 2010 and April 2013, 592 clinical sites randomized and treated 7034 patients (41% from Europe, 20% from North America, and 19% from Asia). At baseline, the mean age was 63 +/- 9 years, BMI 30.6 +/- 5.3 kg/m(2), HbA1c 8.1 +/- 0.8%, and eGFR 74 +/- 21 ml/min/1.73 m(2). The study is expected to report in 2015.
Discussion: EMPA REG OUTCOME (TM) will determine the CV safety of empagliflozin in a cohort of patients with type 2 diabetes and high CV risk, with the potential to show cardioprotection.
Background: Impairments of health related quality of life (HRQoL) are frequently observed in Fabry disease (FD) and are known to be related to neuropathic pain and cardiovascular events. This study aimed to explore the role of chronic kidney disease (CKD) in a large cohort of patients with FD.
Methods: In 96 patients (53% female; age 40 ± 12 yrs) with genetically proven FD, HRQoL was assessed by the Medical Outcomes Study (SF-36) questionnaire. All patients were naïve to enzyme replacement therapy. Three categories for kidney dysfunction were chosen, eGFR ≥/<60 ml/min/1.73 m2 or need of renal replacement therapy (RRT). Minor (e.g. arrhythmia, angina pectoris, etc.) and major (e.g. myocardial infarction, coronary artery bypass, stroke or implantable cardioverter-defibrillator) vascular events as well as pain and pain therapy were considered in linear regression analyses with the dimensions of HRQoL.
Results: Ten patients (10%) had impaired kidney function and a further nine were on RRT (9.4%). Kidney function and pain emerged as the main factors associated with lower scores on the SF 36, in particular on physical components (PCS beta-coefficients for CKD −6.2, for RRT −11.8, for pain −9.1, p < 0.05, respectively), while controlling for gender, vascular event and pain-therapy. Relationships were found for mental aspects of HRQoL. Age and history of vascular events were not related to HRQoL.
Conclusion: Cardiovascular events and pain are important factors related to HRQoL, social functioning and depression. Our study highlights impaired chronic kidney disease, in particular after initiation of RRT, as a strong determinant of reduced HRQoL in FD.
Background
Fabry disease is an inborn lysosomal storage disorder which is associated with small fiber neuropathy. We set out to investigate small fiber conduction in Fabry patients using pain-related evoked potentials (PREP).
Methods
In this case–control study we prospectively studied 76 consecutive Fabry patients for electrical small fiber conduction in correlation with small fiber function and morphology. Data were compared with healthy controls using non-parametric statistical tests. All patients underwent neurological examination and were investigated with pain and depression questionnaires. Small fiber function (quantitative sensory testing, QST), morphology (skin punch biopsy), and electrical conduction (PREP) were assessed and correlated. Patients were stratified for gender and disease severity as reflected by renal function.
Results
All Fabry patients (31 men, 45 women) had small fiber neuropathy. Men with Fabry disease showed impaired cold (p < 0.01) and warm perception (p < 0.05), while women did not differ from controls. Intraepidermal nerve fiber density (IENFD) was reduced at the lower leg (p < 0.001) and the back (p < 0.05) mainly of men with impaired renal function. When investigating A-delta fiber conduction with PREP, men but not women with Fabry disease had lower amplitudes upon stimulation at face (p < 0.01), hands (p < 0.05), and feet (p < 0.01) compared to controls. PREP amplitudes further decreased with advance in disease severity. PREP amplitudes and warm (p < 0.05) and cold detection thresholds (p < 0.01) at the feet correlated positively in male patients.
Conclusion
Small fiber conduction is impaired in men with Fabry disease and worsens with advanced disease severity. PREP are well-suited to measure A-delta fiber conduction.